How to Implement Adaptive Dose-Escalation Designs in Oncology Trials
Adaptive trial design is shaping the future of oncology research.
In our latest guide, Ergomed experts explore how adaptive dose-escalation models such as BOIN and CRM are redefining early-phase oncology studies—enhancing precision, patient safety, and regulatory alignment under FDA’s Project Optimus. From traditional 3+3 models to advanced Bayesian approaches, discover how data-driven design strategies enable smarter dose selection and more efficient trial execution.
Download the guide to learn how adaptive methodologies are driving innovation and improving outcomes in oncology clinical development.